IRIS
SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.473
EU - Europa 1.414
AS - Asia 1.343
SA - Sud America 414
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 93
Totale 6.849
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.375
SG - Singapore 450
BR - Brasile 324
VN - Vietnam 275
IT - Italia 255
RU - Federazione Russa 243
CN - Cina 227
UA - Ucraina 194
SE - Svezia 141
DE - Germania 133
IE - Irlanda 123
TR - Turchia 108
HK - Hong Kong 81
FI - Finlandia 77
FR - Francia 74
DK - Danimarca 68
GB - Regno Unito 53
CI - Costa d'Avorio 40
IN - India 40
CA - Canada 39
KR - Corea 38
BD - Bangladesh 29
AR - Argentina 22
JP - Giappone 21
MA - Marocco 21
MX - Messico 20
CO - Colombia 18
IQ - Iraq 15
NL - Olanda 14
ZA - Sudafrica 14
EC - Ecuador 12
PL - Polonia 10
CL - Cile 9
ID - Indonesia 9
VE - Venezuela 9
ES - Italia 8
IL - Israele 8
PY - Paraguay 7
UY - Uruguay 7
GT - Guatemala 6
MY - Malesia 6
SV - El Salvador 6
BE - Belgio 5
HN - Honduras 5
KE - Kenya 5
PE - Perù 5
PK - Pakistan 5
PR - Porto Rico 5
UZ - Uzbekistan 5
CR - Costa Rica 4
CW - ???statistics.table.value.countryCode.CW??? 4
CZ - Repubblica Ceca 4
EU - Europa 4
PH - Filippine 4
SA - Arabia Saudita 4
SC - Seychelles 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
GP - Guadalupe 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AT - Austria 2
AZ - Azerbaigian 2
DZ - Algeria 2
JM - Giamaica 2
LT - Lituania 2
NI - Nicaragua 2
TW - Taiwan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BM - Bermuda 1
BO - Bolivia 1
BS - Bahamas 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
IM - Isola di Man 1
IR - Iran 1
JO - Giordania 1
KG - Kirghizistan 1
LB - Libano 1
MM - Myanmar 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
TH - Thailandia 1
Totale 6.745
Salva come PNG Salva come JPEG
Città #
Ashburn 669
Singapore 293
Jacksonville 211
Fairfield 210
Chandler 199
San Jose 144
Dublin 121
Dallas 120
Wilmington 120
Council Bluffs 119
Des Moines 100
Boardman 96
New York 96
Woodbridge 95
Ho Chi Minh City 81
Hong Kong 78
Seattle 77
Houston 73
Hanoi 69
The Dalles 67
Beijing 65
Princeton 54
Cambridge 50
Los Angeles 50
Centro 49
Lawrence 47
San Mateo 43
Ann Arbor 42
Lauterbourg 42
Moscow 41
Abidjan 39
Munich 35
São Paulo 29
Turin 29
Helsinki 23
Milan 22
San Diego 22
Chicago 21
London 20
Santa Clara 19
Turku 19
Buffalo 18
Orem 16
Tokyo 15
Hefei 14
Frankfurt am Main 13
Montreal 13
Columbus 12
Porto Alegre 12
Chennai 11
Da Nang 11
Rome 11
Washington 11
Haiphong 10
Johannesburg 9
Phoenix 9
Pune 9
Rio de Janeiro 9
Atlanta 8
Curitiba 8
Denver 8
Naples 8
Paris 8
Shanghai 8
Toronto 8
Amsterdam 7
Guayaquil 7
Irving 7
Montevideo 7
Warsaw 7
Belo Horizonte 6
Brasília 6
Florence 6
Kilburn 6
Mumbai 6
Norwalk 6
Ancona 5
Bogotá 5
Brooklyn 5
Bến Tre 5
Campinas 5
Can Tho 5
Fortaleza 5
Guatemala City 5
Salvador 5
San Salvador 5
Santiago 5
Stockholm 5
Tashkent 5
Thái Nguyên 5
Wuhan 5
Brussels 4
Cagliari 4
Calgary 4
Charleston 4
Charlotte 4
Dhaka 4
Goiânia 4
Izmir 4
Manchester 4
Totale 4.240
Salva come PNG Salva come JPEG
Nome #
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 208
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 207
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 203
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 194
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 183
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 177
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 175
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 167
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 164
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 163
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 163
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 163
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 161
BRAF-mutant colorectal cancer, a different breed evolving 159
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 156
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 153
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 152
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 148
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 147
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 146
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 144
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 144
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 143
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 143
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 143
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 141
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 141
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 138
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 135
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 129
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 128
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 128
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 127
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 124
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 122
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 120
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 119
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 118
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 112
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 111
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 110
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 110
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 109
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 109
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 98
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 95
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res. 2013 Oct;33(10):4611-7 79
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 60
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 48
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers 32
Totale 6.849
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.246
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022250 0 0 0 0 1 28 15 21 24 62 42 57
2022/2023745 52 93 51 42 37 165 0 38 177 5 75 10
2023/2024408 66 8 37 42 62 114 7 12 0 7 10 43
2024/2025866 122 67 15 13 39 41 104 34 162 66 99 104
2025/20262.506 168 211 154 261 300 161 406 245 195 205 80 120
2026/2027512 86 71 94 219 42 0 0 0 0 0 0 0
Totale 6.849